SBTX NASDAQ
Silverback Therapeutics, Inc.
1W: -4.5%
1M: +16.5%
3M: +16.7%
1Y: -33.3%
$5.87
Last traded 2022-11-08 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$550.4M
52W Range2.8-7.545
Volume116,690
Avg Volume172,780
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOPeter A. Thompson
Employees90
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-03
Websitesilverbacktx.com
500 Fairview Avenue North
Seattle, WA 98109
US
Seattle, WA 98109
US
206 456 2900
About Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immune response through the precise activation of TLR8 within the liver. The company was founded in 2016 and maintains its principal offices in Seattle, Washington.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lowenthal Richard E | A-Award | 880,000 | $5.58 | 2024-01-02 |
| Lowenthal Richard E | A-Award | 300,000 | $5.58 | 2024-01-02 |
| Karas Eric | A-Award | 200,000 | $5.58 | 2024-01-02 |
| Tanimoto Sarina | A-Award | 880,000 | $5.58 | 2024-01-02 |
| Tanimoto Sarina | A-Award | 300,000 | $5.58 | 2024-01-02 |